← Benitec Biopharma Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $122k |
$102k
-16.39%
|
$59k
-42.16%
|
$73k
+23.73%
|
$75k
+2.74%
|
$0
-100.00%
|
$3.3m |
$0
-100.00%
|
|
| Revenue Not from Contract with Customer, Other | — | $5k | — | — | — | — | — | — | |
| Cost Of Revenue | ($7.1m) |
$2.8m
+139.80%
|
$7.1m
+153.66%
|
$9k
-99.87%
|
$0
-100.00%
|
$15.5m |
$21.6m
+39.46%
|
— | |
| Gross Profit (derived) | ($7.0m) |
($2.7m)
+60.97%
|
($7.1m)
-161.02%
|
$64k
+100.90%
|
$75k
+17.19%
|
($15.5m)
-20768.00%
|
($18.3m)
-18.26%
|
— | |
| Net Interest Income | $122k | $62k | ($6k) |
($32k)
-433.33%
|
($33k)
-3.12%
|
$904k
+2839.39%
|
$3.3m
+263.50%
|
$5.0m
+53.10%
|
|
| Interest income (expense), net | $122k | $62k | ($6k) |
($32k)
-433.33%
|
($33k)
-3.12%
|
$904k
+2839.39%
|
$3.3m
+263.50%
|
$62k
-98.11%
|
|
| Research and development | $4.6m | $3.0m | $7.0m | $11.3m | $12.8m | $15.6m | $18.3m | $18.4m | |
| General and administrative | $4.6m | $5.6m | $6.5m | $6.6m | $6.4m | $7.0m | $23.4m | $28.2m | |
| Operating Lease, Expense | — | — | — | — | — | — | $400k | — | |
| Other Operating Expenses | — | — | — | $9k | — | ($108k) | — | — | |
| Operating Expenses | $9.6m | $8.4m | $13.7m | $17.9m | $19.2m | $22.5m | $41.8m | $46.6m | |
| Loss from operations | $2.6m |
($8.3m)
-420.60%
|
($13.6m)
-64.18%
|
($17.9m)
-31.32%
|
($19.1m)
-6.87%
|
($22.5m)
-17.87%
|
($41.8m)
-85.70%
|
— | |
| Operating Income (Loss) | $2.6m |
($8.3m)
-420.60%
|
($13.6m)
-64.18%
|
($17.9m)
-31.32%
|
($19.1m)
-6.87%
|
($22.5m)
-17.87%
|
($41.8m)
-85.70%
|
($46.6m)
-11.57%
|
|
| Interest Expense | — | — | — | $32k | $33k | — | — | — | |
| Net Non Operating Interest Income Expense | $122k | $62k | ($6k) | ($32k) | ($33k) | $904k | $3.3m | $5.0m | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($75k) | ($88k) | ($333k) | ($232k) | ($415k) | $40k | ($71k) | — | |
| Unrealized foreign currency translation gain (loss) | ($531k) | ($89k) | $498k | $210k | $415k | ($62k) | $53k | — | |
| Gain On Sale Of Security | — | — | — | ($243k) | ($418k) | $39k | ($71k) | $231k | |
| Other Nonoperating Income (Expense) | — | $34k | $37k | ($79k) | ($30k) | ($204k) | ($131k) | — | |
| Other expense, net | — | $34k | $37k | ($79k) | ($30k) | ($204k) | ($131k) | — | |
| Other Income Expense | — | — | — | ($322k) | ($448k) | ($165k) | $562k | $23k | |
| Total other income (loss), net | $26k | $7k | ($286k) | ($354k) | ($481k) | $739k | $3.8m | — | |
| Interest Income (Expense), Nonoperating, Net | $122k | $62k | ($6k) | ($32k) | ($33k) | $904k | $3.3m | $62k | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($299k) | ($7.9m) | ($17.4m) | ($19.0m) | ($21.0m) | ($37.2m) | ($41.5m) | |
| Pre-Tax Income | $2.6m | ($8.3m) | ($13.9m) | ($18.2m) | ($19.6m) | ($21.8m) | ($37.9m) | ($41.5m) | |
| Net loss | $2.6m | ($8.3m) | ($13.9m) | ($18.2m) | ($19.6m) | ($21.8m) | ($37.9m) | — | |
| Net Income From Continuing And Discontinued Operation | $2.6m | ($8.3m) | ($13.9m) | ($18.2m) | ($19.6m) | ($21.8m) | ($37.9m) | ($41.5m) | |
| Net loss attributable to common shareholders | — | — | — | — | ($19.6m) | ($22.4m) | ($37.9m) | — | |
| Otherunder Preferred Stock Dividend | — | — | — | — | $0 | $619k | $0 | — | |
| Earnings Per Share, Basic | $3.05 | ($8.10) | ($3.23) | ($2.23) | ($14.12) | ($5.51) | ($1.05) | ($0.93) | |
| Earnings Per Share, Diluted | $3.05 | ($8.10) | ($3.23) | ($2.23) | ($14.12) | ($5.51) | ($1.05) | ($0.93) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | 4.3m | 8.2m | 1.4m | 4.1m | 36.2m | 44.5m | |
| Basic Average Shares | — | — | — | $481k | $1.4m | $18.4m | $36.2m | $44.5m | |
| Diluted Average Shares | — | — | — | $481k | $1.4m | $18.4m | $36.2m | $44.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | 4.3m | 8.2m | 1.4m | 4.1m | 36.2m | 44.5m | |
| Additional Financial Items | |||||||||
| Royalties and license fees | $435k | ($185k) | $123k | $9k | $0 | ($108k) | $0 | — | |
| Gain on extinguishment of liabilities | — | — | — | — | — | $0 | $764k | — | |
| Unrealized loss on investment | ($21k) | ($1k) | $16k | ($11k) | ($3k) | ($1k) | $0 | — | |
| Deemed dividends | — | — | — | — | $0 | ($619k) | $0 | — | |
| Diluted EPS | — | — | — | ($37.91) | ($14.12) | ($1.22) | ($1.05) | ($0.93) | |
| Diluted NI Availto Com Stockholders | — | — | — | ($18.2m) | ($19.6m) | ($22.4m) | ($37.9m) | ($41.5m) | |
| Normalized EBITDA | — | — | — | ($17.5m) | ($18.3m) | ($22.2m) | ($41.3m) | ($46.1m) | |
| Normalized Income | — | — | — | ($18.0m) | ($19.1m) | ($21.8m) | ($37.8m) | ($41.8m) | |
| Other Gand A | $4.6m | $5.6m | $6.5m | $6.6m | $6.4m | $7.0m | $23.4m | — | |
| Reconciled Depreciation | — | — | — | $392k | $381k | $343k | $396k | $475k | |
| Salaries And Wages | — | — | — | $613k | $291k | — | — | $291k | |
| Selling General And Administration | $4.6m | $5.6m | $6.5m | $6.6m | $6.4m | $7.0m | $23.4m | — | |
| Special Income Charges | — | — | — | — | — | $0 | $764k | $0 | |
| Tax Effect Of Unusual Items | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Tax Rate For Calcs | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Total other comprehensive income (loss) | ($531k) | ($89k) | $498k | $210k | $415k | ($62k) | $53k | — | |
| Total comprehensive loss | $2.1m | ($8.4m) | ($13.4m) | ($18.0m) | ($19.1m) | ($21.8m) | ($37.9m) | — | |
| Total Unusual Items | — | — | — | ($243k) | ($418k) | $39k | ($71k) | $231k | |
| Total Expenses | $9.6m | $8.4m | $13.7m | $17.9m | $19.2m | $22.5m | $41.8m | $46.6m | |
| Total Other Finance Cost | — | — | — | — | $33k | ($904k) | ($3.3m) | ($4.3m) |